Skip to content

Vera Therapeutics VERA Free cash flow

Free cash flow at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.29B+66.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$95.07M+14.2%
Alumis Inc. logo
Alumis Inc.ALMS
-$87.25M-8.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Calculated from Vera Therapeutics’s reported figures.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's free cash flow?
Vera Therapeutics (VERA) reported free cash flow of -$106.52M in Q1 2026.
How has Vera Therapeutics's free cash flow changed year-over-year?
Vera Therapeutics's free cash flow decreased by 95.1% year-over-year, from -$54.59M to -$106.52M.
What is the long-term trend for Vera Therapeutics's free cash flow?
Over 4 years (2021 to 2025), Vera Therapeutics's free cash flow has grown at a 78.7% compound annual growth rate (CAGR), from -$23.71M to -$241.73M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.